代谢相关脂肪性肝病自然史研究进展

doi:10.3969/j.issn.1672-5069.2023.06.001

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 769-772.doi: 10.3969/j.issn.1672-5069.2023.06.001

• 专家论坛 • 下一篇

代谢相关脂肪性肝病自然史研究进展

曾静, 范建高

200092 上海市上海交通大学医学院附属新华医院消化内科

收稿日期:2023-09-20 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 范建高,E-mail:fattyliver2004@126.com
作者简介:曾静,女,33岁,医学博士,主治医师。E-mail: zjupup@126.com

Natural history of metabolic dysfunction-associated fatty liver diseases

Zeng Jing, Fan Jiangao

Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China

Received:2023-09-20 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 代谢相关脂肪性肝病, 自然史

Key words: Non-alcoholic fatty liver diseases, Metabolic dysfunction-associated fatty liver diseases, Natural history

曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.

Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.

[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1):202-209.
[2] Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol,2023,S0168-8278(23)00418-X.
[3] 范建高,李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志, 2023,31(8):789-792.
[4] Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism,2013,62(3):352-360.
[5] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64(1):73-84.
[6] Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med,2021,385(17):1559-1569.
[7] Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology,2020,71(3):808-819.
[8] Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol,2023,78(3):471-478.
[9] Thomas JA, Kendall BJ, Dalais C, et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer,2022,173:250-262.
[10] Männistö VT, Salomaa V, Färkkilä M, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int,2021,41(11):2590-2600.
[11] Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology,2020,72(5):1605-1616.
[12] Toh JZK, Pan XH, Tay PWL, et al. A Meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2022,20(11):2462-2473,e10.
[13] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2021,6(11):903-913.
[14] Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut,2022,2022-327672.
[15] Tang ASP, Chan KE, Quek J, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clin Mol Hepatol,2022,28(3):483-496.
[16] Zhang RN, Fan JG. Editorial: opposite effects of genetic polymorphisms known to induce NAFLD on hepatic and cardiovascular outcomes in Chinese population. Aliment Pharmacol Ther,2022,55(7):876-877.
[17] Wang Z, Zhao X, Chen S, et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol,2021,19(4):788-796,e4.
[18] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut,2022,71(4):778-788.
[19] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut,2021,70(5):962-969.
[20] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut,2022,71(1):156-162.
[21] Zou ZY, Fan JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. J Hepatol,2020,73(1):214-216.
[22] Ayada I, van Kleef LA, Alferink LJM,et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int,2022,42(2):277-287.
[23] Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology,2022,76(5):1423-1437.
[24] Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol,2021,75(6): 1284-1291.
[25] van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep,2021,3(5):100350.
[26] 顾棨, 芮法娟, 倪文婧, 等. 非酒精性脂肪性肝病的规范化管理. 实用肝脏病杂志,2023,26(4):457-459.
[27] 张淮, 郑明华. MAFLD高危人群的筛查和分层管理. 实用肝脏病杂志,2023,26(4):463-466.
[28] 何方平. 我国NAFLD慢病管理实践现状和建议. 实用肝脏病杂志, 2023,26(4):460-462.

代谢相关脂肪性肝病自然史研究进展

Natural history of metabolic dysfunction-associated fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[2]	卢蓉, 李慧, 张超, 邵正健, 罗大光. 甘油三酯/葡萄糖指数预测非酒精性脂肪性肝病严重程度效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 805-810.
[3]	邵孝如, 周筱, 葛颖颖. ¹⁸F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 811-814.
[4]	丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.
[5]	侯义林, 曹风华, 纪小燕, 蔡燕. 非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 819-822.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	韩仕杉, 赵彩彦. Betatrophin与非酒精性脂肪性肝病[J]. 实用肝脏病杂志, 2023, 26(6): 930-933.
[8]	吴非, 郭雯, 张群. 非酒精性脂肪性肝病患者骨骼肌质量变化研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 646-649.
[9]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[10]	蔡欣, 辛春红, 牛洪凯, 兰春祥. 代谢相关脂肪性肝病患者血清HIF-1α、Chemerin和脂联素水平变化及临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 654-657.
[11]	黄龙, 范雅茜, 段钟平. 舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*[J]. 实用肝脏病杂志, 2023, 26(5): 765-768.
[12]	顾棨, 芮法娟, 倪文婧, 陈倩倩, 吴超, 施军平, 李婕. 非酒精性脂肪性肝病的规范化管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 457-459.
[13]	何方平. 我国NAFLD慢病管理实践现状和建议[J]. 实用肝脏病杂志, 2023, 26(4): 460-462.
[14]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[15]	尹会芬, 于红艳, 刘志平. 非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 500-503.